Ivosidenib Shows Activity in IDH1-Mutant Myelodysplastic Neoplasms
The French Myelodysplasia Group reported Phase II IDIOME results for single-agent ivosidenib in 48 older adults with IDH1-mutant myelodysplastic neoplasms. Overall response after three cycles was 63.6% in higher-risk disease after azacitidine failure and…
